Amphotericin B inhalation
Alternative Names: ABIP; Amphotericin B inhalation powder; NKTR-024Latest Information Update: 02 Oct 2021
At a glance
- Originator Nektar Therapeutics
- Class Antifungals; Antiprotozoals; Macrolides
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Aspergillosis
Most Recent Events
- 16 Jul 2010 No development reported - Phase-I for Aspergillosis in USA (Inhalation)
- 31 Dec 2008 Novartis acquires amphotericin B programme
- 21 Oct 2008 Novartis agrees to acquire amphotericin B programme